Regenxbio (RGNX) Cash & Equivalents (2014 - 2026)
Regenxbio (RGNX) reported Cash & Equivalents of $36.49 million for Q2 2026, down 54.1% from $79.56 million a year earlier.
Powered by 
Analysis
Regenxbio (RGNX) Cash & Equivalents (2014 - 2026) Analysis & Trends
At the end of FY2025, Regenxbio posted Cash & Equivalents of $34.47 million, down 40.1% from FY2024.
- Cash & Equivalents has a five-year compound annual growth rate of -36.7% (FY2020 to FY2025).
- By year, Cash & Equivalents came in at $57.53 million in FY2024 (+66.6%), $34.52 million in FY2023 (-64.4%), $96.95 million in FY2022 (-71.9%) and $345.21 million in FY2021 (+2.0%).
- Five-year quarterly Cash & Equivalents spans a low of $34.47 million in Q4 2025 and a high of $345.21 million in Q4 2021.
- Year over year, Cash & Equivalents gained in five of the last seven quarters, with growth averaging 5.1%.
- The high point for year-over-year Cash & Equivalents in five years was Q3 2021 (growth of 145.0%); the low point was Q4 2022 (a decline of 71.9%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Regenxbio | 402.44 Mn | -530.65 Mn | - | 36.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.49 Mn |
| Dec 31, 2025 | 34.47 Mn |
| Sep 30, 2025 | 58.80 Mn |
| Jun 30, 2025 | 79.56 Mn |
| Mar 31, 2025 | 130.10 Mn |
| Dec 31, 2024 | 57.53 Mn |
| Sep 30, 2024 | 56.62 Mn |
| Jun 30, 2024 | 57.77 Mn |
| Mar 31, 2024 | 112.98 Mn |
| Dec 31, 2023 | 34.52 Mn |
| Sep 30, 2023 | 53.05 Mn |
| Jun 30, 2023 | 68.60 Mn |
| Mar 31, 2023 | 70.09 Mn |
| Dec 31, 2022 | 96.95 Mn |
| Sep 30, 2022 | 118.54 Mn |
| Jun 30, 2022 | 121.37 Mn |
| Mar 31, 2022 | 191.87 Mn |
| Dec 31, 2021 | 345.21 Mn |
| Sep 30, 2021 | 228.39 Mn |
| Jun 30, 2021 | 257.07 Mn |
API Access
Regenxbio Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RGNX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "RGNX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RGNX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();